AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.
in order to develop and commercialise Amylin’s existing portfolio of products, which has a main focus on the R&,D of treatments for patients with type 2 diabetes. AstraZeneca will pay Bristol ...
The South African Health Products Regulatory Authority ... are a class of medications that can help manage diabetes and ...
AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company ...
With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...
Hosted on MSN1d
AstraZeneca Q2 net profit declines 10%, revenue up 31%Mumbai: AstraZeneca Pharma India Ltd posted a profit after tax ... The company’s growth was driven by its portfolio of ...
Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback